ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on drug CONCORD, Mass., Oct. 22, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating…